Incyte data positive, says Oppenheimer After Incyte reported results for ruxolitinib in pancreatic cancer, Oppenheimer thinks the data supports the evaluation of ruxolitinib in a wide range of tumor types. Following the results of an IDO + ipilimumab proof-of-concept study in melanoma, Oppenheimer finds the results encouraging. The firm keeps a $75 price target on the shares and reiterates an Outperform rating.
Incyte data promising, says SunTrust SunTrust believes that the data for Incyte's JAK1/PI3K combination in NHL and HL is promising. The firm says that the combo shows early signs of activity in B cell malignancies. It keeps a $120 price target and Buy rating on the shares.